Objective: To describe the differences in multiple factors based on Parkinson’s treatment in patients with impulse control disorder

Background: In intermediate-advanced phases of PE, psychiatric disorders secondary to dopaminergic therapy are expected, including impulse control disorders. [2]. ICT behaviors have been performed repeatedly, excessively, and compulsively, to the point of interfering with the patient’s functionality and daily life (3). Different ICDs have been described in the general population, including gambling disorders, compulsive eating, compulsive buying, hypersexuality, pyromaniacs, kleptomania, and intermittent explosive disorder [1]. 

Among the risk factors we find the use of dopaminergic agonists increases the risk by 2 to 3. 5 times, which can occur with any type of agonist. Another drug associated with increased risk is levodopa (especially at high doses), as well as other factors such as the male gender[2]. One of the problems we face with ICDs in PE is the difficulty, in many cases, of establishing the diagnosis. Not all patients are aware of their problems [3].

Method:

We performed an observational retrospective cross-sectional study in which we included patients of both sex with ICD from a Mexican Institute. The division of sample was into three groups, Group 1: patients who are under treatment with levodopa, Group 2: Patients who are under treatment with a dopamine agonist, and Group 3: Patients with both treatments. The three groups applied MDS-UPDRS 1.6 for dopaminergic regulation, NMSUPDRS 3.3 total for the evolution of PD, and age based on the date of birth.

Results: 100 patients included: 54 males (50.9%), and 46 females (43.4%). The mean age was 65.79 +/- 12.9 años. Regarding the type of medication being consumed, patient 8 takes agonist (7.5), 28 levodopa (26.4), and both 64 (60.4).

The results using ANOVA in the age of the patient (p= 0.045), 58.63 for group 1, 70.21 for group 2, 60.74 for group 3, MDS.UPDRS 3.3 (p=0.135), 23.63 for group 1, 34.18 for group 2, 29.34 for group 3.

Xi2 was used to analyze gender and dopaminergic dysregulation and it is reported that there is no significant difference between the groups.

Conclusion: The results suggest a difference in the age in the three groups, and there is no difference in MDS-UPDRS 1.6, MDS-UPDRS 3.3 total, and gender about the treatment.

References: N. Saez-Francàs a, G. Martí Andrés b, N. Ramírez a, O. de Fàbregues b, J. Álvarez-Sabín b, M. Casas c, J. Hernández-Vara b. Clinical and psychopathological factors associated with impulse control disorders in Parkinson’s disease. Neurología. 2016 May, 31 (1): 231-238. Doi: https://doi.org/10.1016/j.nrl.2015.05.002
Gabriel José Arango Uribe, Oscar Bernal Pacheco. Impulse control disorders (ICD) in Parkinson’s disease. Consenso. 2019 July. 35 (3).28-32. Doi: https://doi.org/10.22379/24224022247
A. Ávila, X. Cardona, J. Bello, P. Maho, F. Sastre, M. Martín Baranera. Impulse control disorders and punding in Parkinson’s disease: a structured interview is needed. Neurología. 2011. 26(3). 166-172. Doi: https://doi.org/10.1016/S2173-5808(11)70033-5

« Back to 2023 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/differences-in-patients-with-impulse-control-disorder-based-on-antiparkinsonian-drug-treatment-in-a-mexican-institute/